A small study testing the pharmacodynamic effects of several antiplatelet agents suggests that tirofiban (Aggrastat; Medicure), a glycoprotein IIb/IIIa inhibitor, may provide “more potent and ...
Please provide your email address to receive an email when new articles are posted on . The study, which was presented at the virtual PCR e-Course and simultaneously published in Circulation, also ...
Widely prescribed blood thinners such as COX-1 inhibitor aspirin and P2Y12 antagonist Plavix have a common problem: By decreasing platelet aggregation, they also increase the risk of uncontrolled ...
SAN DIEGO---CeleCor Therapeutics, Inc. today announced preliminary positive results in the company’s ongoing phase 1 clinical study with RUC-4, a novel subcutaneous platelet GPIIb/IIIa inhibitor, ...
SAN DIEGO--(BUSINESS WIRE)--CeleCor Therapeutics, Inc. announced positive data from the company’s completed phase 1 clinical study of RUC-4 which was published in the Journal of the American Heart ...
An international team of researchers in cooperation with the University of Bonn has taken two "snapshots" of a receptor which are of critical importance for blood coagulation. The scientists now hope ...
A recently recognized drug-drug interaction between opioids and P2Y12 inhibitors may have clinical implications for patients with ACS. Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is ...
NEW ORLEANS -- An antidote to ticagrelor (Brilinta) provided quick and sustained reversal of the antiplatelet's effects in a small phase I trial, according to researchers here. Experiments showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results